Pancreatic cancer: From molecular signature to target therapy

Critical Reviews in Oncology/Hematology

Volumn 68, Issue 3, 2008, Pages 197-211

  Longo, R ^a   Cacciamani, F ^a   Naso, G ^b   Gasparini, G ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Epidermal growth factor receptor; Erlotinib; Pancreatic cancer

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GEFITINIB; GEMCITABINE; MARIMASTAT; MATUZUMAB; NIMESULIDE; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; TANOMASTAT; THALIDOMIDE; TIPIFARNIB; TRASTUZUMAB; VASCULOTROPIN;

ABDOMINAL INFECTION; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC THERAPY; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA IN SITU; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; INTESTINE PERFORATION; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPENIC SEPSIS; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS INTRAEPITHELIAL NEOPLASIA; PLEURA EFFUSION; PNEUMONIA; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; RADIATION DOSE; RASH; REVIEW; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SMALL INTESTINE DISEASE; SMALL INTESTINE LEAK; SMALL INTESTINE OBSTRUCTION; SMALL INTESTINE PERFORATION; STOMACH PERFORATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS;

EID: 54349110130     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.03.003     Document Type: Review

References (109)

1. Verslype C., Van Cutsem E., Dicato M., Cascinu S., Cunningham D., Diaz-Rubio E., et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 18 Suppl. 7 (2007) vii1-vii10
2. Li D., Xie K., Wolff R., and Abbruzzese J.L. Pancreatic cancer. Lancet 363 (2004) 1049-1057
3. Sakorafas G.H., Tsiotou A.G., and Tsiotos G.G. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 26 (2000) 29-52
4. Neoptolemos J.P., Dunn J.A., Stocken D.D., Almond J., Link K., Beger H., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer. A randomized controlled trial. Lancet 358 (2001) 1576-1585
5. Abbruzzese J.L. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95 (2002) 941-945
6. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
7. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
8. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 297 (2007) 267-277
9. Rocha Lima C.M., Green M.R., Rotche R., Miller Jr. W.H., Jeffrey G.M., Cisar L.A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (2004) 3776-3783
10. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., André T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
11. Canto M.I., Goggins M., Yeo C.J., Griffin C., Axilbund J.E., Brune K., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2 (2004) 606-621
12. Hruban R.H., Wilentz R.E., and Kern S.E. Genetic progression in the pancreatic ducts. Am J Pathol 156 (2000) 1821-1825
13. Kinzler K.W., and Vogelstein B. Cancer-susceptibility genes: gate-keepers and caretakers. Nature 386 (1997) 761-763
14. Lüttges J., Schlehe B., Menke M.A., Vogel I., Henne-Bruns D., Klöppel G., et al. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic and metaplastic ductal epithelium. Cancer 85 (1999) 1703-1710
15. Tada M., Ohashi M., Stiratori Y., Okudaira T., Komatsu Y., Kawabe T., et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110 (1996) 227-231
16. Biankin A.V., Kench J.G., Morey A.L., Lee C.S., Biankin S.A., Head D.R., et al. Overexpression of p21WAF/CIP1 is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 61 (2001) 8830-8837
17. Wilentz R.E., Geradts J., Maynard R., Offerhaus G.J., Kang M., Goggins M., et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 58 (1998) 4740-4744
18. Moskaluk C.A., Hruban R.H., and Kern S.E. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 84 (1997) 2140-2143
19. Di Giuseppe J.A., Hruban R.H., Goodman S.N., Polak M., van den Berg F.M., Allison D.C., et al. Overexpression of p 53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 101 (1994) 684-688
20. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., Sipos B., Hahn S.A., Klein-Scory S., et al. Smad4/DPC4 mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 97 (2000) 9624-9629
21. Heinmoller E., Dietmaier W., Zirngibl H., Heinmöller P., Scaringe W., Jauch K.W., et al. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 157 (2000) 83-92
22. Luttges J., Galehdari H., Brocker V., Schwarte-Waldhoff I., Henne-Bruns D., Klöppel G., et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 158 (2001) 1677-1683
23. Tascilar M., Skinner H.G., Rosty C., Sohn T., Wilentz R.E., Offerhaus G.J., et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7 (2001) 4115-4121
24. Van Heek N.T., Meeker A.K., Kern S.E., Yeo C.J., Lillemoe K.D., Cameron J.L., et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161 (2002) 1541-1547
25. Maitra A., Adsay N.V., Argani P., Iacobuzio-Donahue C., De Marzo A., Cameron J.L., et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16 (2003) 902-912
26. Islam H.K., Fujioka Y., Tomidokoro T., Sugiura H., Takahashi T., Kondo S., et al. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas. Hepatogastroenterology 48 (2001) 879-883
27. Kitada T., Seki S., Sakaguchi H., Sawada T., Hirakawa K., and Wakasa K. Clinicopathological significance of hypoxia-inducible factor-1a expression in human pancreatic carcinoma. Histopathology 43 (2003) 550-555
28. Duffy J.P., Eibl G., Reber H.A., and Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2 (2003) 12
29. Silletti S., Paku S., and Raz A. Tumor cell motility and metastasis autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol Oncol Res 3 (1997) 230-254
30. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
31. Kuwahara K., Sasaki T., Kuwada Y., Murakami M., Yamasaki S., and Chayama K. Expression of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 26 (2003) 344-349
32. Ikeda N., Nakajima Y., Tokuhara T., Hattori N., Sho M., Kanehiro H., et al. Clinical significance of aminopeptide N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 9 (2003) 1503-1508
33. Uehara H., Miyamoto M., Kato K., Ebihara Y., Kaneko H., Hashimoto H., et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 64 (2004) 3533-3537
34. Xiong H.Q., and Abbruzzese J.L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29 5 Suppl. 14 (2002) 31-37
35. Yamanaka Y., Friess H., Kobrin M.S., Buchler M., Beger H.G., and Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13 (1993) 565-569
36. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29 (2004) e1-e8
37. Kim S.G., Wu T.T., Lee J.H., Yun Y.K., Issa J.P., Hamilton S.R., et al. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol 16 (2003) 1086-1094
38. Abraham S.C., Klimstra D.S., Wilentz R.E., Yeo C.J., Conlon K., Brennan M., et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor β-catenin mutations. Am J Pathol 160 (2002) 1361-1369
39. Porta M., Malats N., Jariod M., Grimalt J.O., Rifà J., Carrato A., et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 354 (1999) 2125-2129
40. Duell E.J., Holly E.A., Bracci P.M., Wiencke J.K., and Kelsey K.T. A population-based study of the Arg399Gln polymorphism in X-ray repair cross-complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 62 (2002) 4630-4636
41. Kume K., Masamune A., Mizutamari H., Kaneko K., Kikuta K., Satoh M., et al. Mutations in the serine protease inhibitor Kazal type 1 (SPINK1) gene in Japanese patients with pancreatitis. Pancreatology 5 (2005) 354-360
42. Klein A.P. Overview of linkage analysis: application to pancreatic cancer. Methods Mol Med 103 (2005) 329-341
43. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
44. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., and Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 (2002) 161-167
45. Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., and Buckels J.A. Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19 (2001) 3447-3455
46. Gatto C., Rieppi M., Borsotti P., Innocenti S., Ceruti R., Drudis T., et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 5 (1999) 3603-3607
47. Erlichman C., Adjei A.A., Alberts S.R., Sloan J.A., Goldberg R.M., Pitot H.C., et al. Phase I study of the matrix metalloproteinase inhibitor BAY 12-9566. Ann Oncol 12 (2001) 389-395
48. Heath E.I., O'Reilly S., Humphrey R., Sundaresan P., Donehower R.C., Sartorius S., et al. Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumours. Cancer Chemother Pharmacol 48 (2001) 269-274
49. Hirte H., Goel R., Major P., Seymour L., Huan S., Stewart D., et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 11 (2000) 1579-1584
50. Moore M.J., Hamm J., Dancey J., Eisenberg P.D., Dagenais M., Fields A., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3296-3302
51. Seo Y., Baba H., Fukuda T., Takashima M., and Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 (2000) 2239-2245
52. Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J.W., Richter A., et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25 (2002) 122-129
53. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 31 (2005) 8033-8040
54. Heinemann V., Wilke H., Mergenthaler H.G., Clemens M., König H., Illiger H.J., et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11 (2000) 1399-1403
55. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
56. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
57. Sorensen H.T., Mellemkjaer L., Olsen J.H., and Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
58. Kindler H.L., Niedzwiecki D., Hollis D., Oraef E., Schrag D., Hurwitz H., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). 2007 ASCO Annual Meeting Proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 4508
59. Astsaturov N.J., Meropol N.J., Alpaugh R.K., Cheng J.D., Lewis N.L., Beard A., et al. A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. 2007 ASCO Annual Meeting Proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 4556
60. Kim G.P., Oberg A.L., Foster N.R., Jaslowski A., Flynn P.J., Campbell D., et al. Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. 2007 ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 4553
61. Crane C.H., Ellis M., Abbruzzese J.L., Douglas E.B., Henry H., Ho L., et al. Phase I trial of bevacizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenocarcinoma (PA). J Clin Oncol 23 Suppl. (2005) 4033
62. Small W., Mulcahy M., Benson A., Gold S., Bredesen R., Rademaker F., et al. A phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer. 2007 ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 15043
63. Zhou X.C., Tang C.W., Liu C.L., and Wang C.H. Effects of rofecoxib on angiogenesis of pancreatic cancer xenograft in nude mice. Ai Zheng 23 4 (2004) 376-380
64. Wang H.X., and Chen Q.K. Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas. Ai Zheng 22 6 (2003) 649-652
65. Crane H., Mason K., Janjan N.A., and Milas L. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol 26 4 (2003) S81-S84
66. Milella M., Gelibter A., Di Cosimo S., Bria E., Ruggeri E.M., Carlini P., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101 1 (2004) 133-138
67. Xiong H.Q., Hess K.R., Kayaleh O.R., Goodwin W., Banerjee T., Sinclair S.S., et al. A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer. J Clin Oncol 23 Suppl. (2005) 4174
68. Brophy J.M. Celecoxib and cardiovascular risks. Exp Opin Drug Saf 4 (2005) 1005-1015
69. Ferrari V., Valcamonico F., Amoroso V., Simoncini E., Vassalli L., Marpicati P., et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 57 2 (2006) 185-190
70. El-Rayes B.F., Zalupski M.M., Shields A.F., Ferris A.M., Vaishampayan U., Heilbrun L.K., et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 23 6 (2005) 583-590
71. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., and Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by non-steroidal anti-inflammatory drugs. Cancer Res 59 17 (1999) 4356-4362
72. Eibl G., Takata Y., Boros L.G., Liu J., Okada Y., Reber H.A., et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 65 3 (2005) 982-990
73. Ali S., El-Rayes B.F., Sarkar F.H., and Philip P.A. Simultaneous targeting of epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4 12 (2005) 1943-1951
74. Teo S.K., Stirling D.I., and Zeldis J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 10 (2005) 107-114
75. Vacca A., Scavelli C., Montefusco V., Di Pietro G., Neri A., Mattioli M., et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23 (2005) 5334-5346
76. Densmore J.J., Fox J.R., Kannarkat G., Morgan J.K., Petroni G., Blount T., et al. A phase I/II trial of weekly gemcitabine with celecoxib and thalidomide for patients with advanced pancreatic cancer. J Clin Oncol 23 Suppl. (2005) 4241
77. Dredge K., Marriott J.B., and Dalgleish A.G. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 22 (2002) 425-437
78. Gordon J.N., Trebble T.M., Ellis R.D., Duncan H.D., Johns T., and Goggin P.M. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54 (2005) 540-545
79. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (2001) 32s-40s
80. Xiong H.Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R.A., Deutsch J., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22 (2004) 2610-2616
81. Philip P.A., Benedetti J., Fenoglio-Preiser C., Zalupski M., Lenz H., O'Reilly E., et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. 2007 ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) LBA4509
82. Cascinu S., Berardi R., Siena S., La bianca R., Falcone A., Aitini E., et al. The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): a randomized phase II trial of GISCAD. ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 4544
83. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72 (2004) 257-266
84. Bowers G., Reardon D., Hewitt T., Dent P., Mikkelsen R.B., Valerie K., et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 20 (2001) 1388-1397
85. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., Todd D.G., Valerie K., Kavanagh B.D., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
86. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
87. Buchsbaum D.J., Bonner J.A., Grizzle W.E., Stackhouse M.A., Carpenter M., Hicklin D.J., et al. Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 54 (2002) 1180-1193
88. Krempien R., Munter M.W., Timke C., Friess H., Hartung G., Herfarth K.K., et al. Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: a prospective phase II trial. 2007 ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 4573
89. Graeven U., Kremer B., Sudhoff T., Killing B., Rojo F., Weber D., et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94 (2006) 1293-1299
90. Strumberg D., Scheulen M.E., Hilger R.A., Krauss J., Marschner N., Lordick F., et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). 2006 ASCO annual meeting proceedings. Part I. Vol. 24, no. 18S (June 20 supplement). J Clin Oncol (2006) 12504
91. Burris III H.A. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 32 4 Suppl. 6 (2005) S1-S3
92. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
93. Blaszkowsky L.S., Kulke K.H., Ryan D.P., Clark J.W., Meyerhardt J., Zhu A.X., et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. 2005 ASCO Annual Meeting Proceedings. Part I. Vol. 23, no. 16S (June 1 supplement). J Clin Oncol (2005) 4099
94. Gomez-Martin C., Camara J.C., Cortes H., Jara C., Gravalos C., Rubio B., et al. A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer. 2007 ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 4611
95. Shadad F., Matin K., Evans T., Volkin R.L., Kiefer G.J., Schlesselman J.J., et al. Phase II study of gefitinib and docetaxel as salvage therapy in patients (pts) with advanced pancreatic adenocarcinoma (APC). 2006 ASCO Annual Meeting Proceedings. Part I. Vol. 24, no. 18S (June 20 supplement). J Clin Oncol (2006) 4120
96. Fountzilas G., Murray S., Xiros N., Karayannopoulou G., Dafni U., Linardou H., et al. Gemcitabine (G) combined with gefitinib in patients with inoperable or metastatic pancreatic cancer. A phase II trial. ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 15016
97. Brell J.M., Matin K., Evans T., Volkin R.L., Keifer G.J., Schlesselman J.J., et al. Phase II study of gefitinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after first-line therapy. Final results. 2007 ASCO annual meeting proceedings. Part I. Vol. 25, no. 18S (June 20 supplement). J Clin Oncol (2007) 4586
98. Kindler H., Bylow K.A., Hochster H., Friberg G., Micetich H., Locker G., et al. A randomized phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer: a preliminary analysis. 2006 ASCO Annual Meeting Proceedings. Part I. Vol. 24, no. 18S (June 20 supplement). J Clin Oncol (2006) 4040
99. Iannitti D., Dipetrillo T., Akerman P., Barnett J.M., Maia-Acuna C., Cruff D., et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28 (2005) 570-575
100. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61 (2001) 131-137
101. Lobell R.B., Omer C.A., Abrams M.T., Bhimnathwala H.G., Brucker M.J., Buser C.A., et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 61 (2001) 8758-8768
102. Macdonald J.S., Chansky K., Whitehead R., Wade J., Giguere J., Abbruzzese J.L., et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG) study. J Clin Oncol 21 (2003) 1301-1306
103. Hudes G.R., Schol J., Baab J., Rogatko A., Bol C., Horak I., et al. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. 1999 ASCO Annual Meeting Proceedings. Part I. Vol. 18 (1999) 601
104. Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne V.V.L., Szawlowski A., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22 (2004) 1430-1438
105. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
106. Yamanaka Y., Friess H., Kobrin M.S., Buchler M., Kunz J., Beger H.G., et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24 (1993) 1127-1134
107. Safran H., Steinhoff M., Mangray S., Rathore R., King T.C., Chai L., et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24 (2001) 496-499
108. Buchler P., Reber H.A., Buchler M.C., Roth M.A., Buchler M.W., Friess H., et al. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 5 (2001) 139-146
109. Safran H., Iannitti D., Ramanathan R., Schwartz J.D., Steinhoff M., Nauman C., et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22 (2004) 706-712